Introduction
============

Postmenopausal osteoporosis (PO), one type of osteoporosis, is believed to result directly from the decreased endogenous estrogen in menopausal women ([@b1-etm-0-0-7310],[@b2-etm-0-0-7310]). The measurement of bone mineral density (BMD) has been regarded as the 'gold standard' in osteoporosis diagnosis ([@b3-etm-0-0-7310]). Therefore, extraction of genes predisposing to BMD will be beneficial for the understanding of genetic mechanisms and aid in developing novel treatment of PO and PO-related fractures.

An increasing number of genes has been identified to have independent effects on BMD in osteoporosis in recent years. For example, POSTN, a regulator of osteoblast differentiation and bone formation, has been demonstrated to influence the susceptibility to low BMD and osteoporosis ([@b4-etm-0-0-7310]). Moreover, genes VDR, ESR1, NRIP1 in B cells have been reported to be closely associated with BMD in patients with osteoporosis ([@b5-etm-0-0-7310]). Furthermore, Jemtland *et al* ([@b6-etm-0-0-7310]) measured the changes in 84 bone biopsies related to BMD variations in postmenopausal women to extract osteoporosis-associated candidate genes and detected that SOX4, MMP13, and MEPE were all under-expressed. Nevertheless, these studies paid main attention on the gene levels related to the BMD, not an intensive analysis of the metabolites in PO.

In 2008, Xiao *et al* ([@b7-etm-0-0-7310]) provided the gene profile data of E-GEOD-7429, analyzing the gene expression profile in B cells of PO patients and identified that downregulation of ESR1 and MAPK3 in B cells led to the increased osteoclastogenesis or decreased osteoblastogenesis. Moreover, in 2016, Ma *et al* ([@b8-etm-0-0-7310]) used this microarray data (E-GEOD-7429) to identify several crucial genes related to PO, and found that the interactions, for example, CSTA/TYROBP, CCNE1/REL and TUBA1B/ESR1 may play an important role in the development of PO. However, these analyses are mainly focused on identifying altered genes between disease and control groups, and do not perform the corresponding analysis for identifying metabolites. Metabolites, the end products of biological regulatory process, are regarded as the final response of biological systems to the changes of environment or inheritance ([@b9-etm-0-0-7310]). Significantly, detecting and prioritizing disease-associated metabolites is crucial for our understanding of metabolite processes to improve medicine ([@b10-etm-0-0-7310]). As reported, metabolites rarely play an important role in isolation, but they exert a key function in the connection of phenotypes as well as genotypes, which are frequently influenced by genome and phenome ([@b11-etm-0-0-7310]). With the development of various 'omics' information, genomic, metabolic, as well as phenomic data, offer valuable information for disease risk candidate metabolites prioritization. Fortunately, Yao *et al* have prioritized several candidate metabolites using multi-omics composite network ([@b12-etm-0-0-7310]). Complementarily, we used multi-omics composite network to screen the metabolite in PO. Our efforts aimed to characterize new metabolite biomarkers as tools allowing for better diagnosis and preventing the progression of PO in the future.

Materials and methods
=====================

The present analysis was comprised of the following steps: microarray data selection (E-GEOD-7429) and identification of differentially expressed genes (DEGs), construction of a weighted composite network through integrating six data sets, and prioritization of candidate metabolites. The detailed information of each step is described in [Fig. 1](#f1-etm-0-0-7310){ref-type="fig"}.

### Data set

With the goal of revealing the molecular mechanisms of PO, microarray analyses of monocytes were performed using microarray data (accession number: E-GEOD-7429) ([@b7-etm-0-0-7310]) which were downloaded from the ArrayExpress database. A total of 20 samples were available. B cells were isolated from the whole blood of 20 unrelated postmenopausal women 54--60 years of age, including 10 with high BMD and 10 with low BMD. The platform of E-GEOD-7429 was A-AFFY-33-Affymetrix GeneChip Human Genome HG-U133A \[HG-U133A\].

### Data pretreatment and DEGs identification

Probe IDs having concentrated expression level were transformed into human gene symbols. Duplicated genes of expression value in matrix were then eliminated. Overall, 12,437 genes were obtained. As known, the difference of gene expression levels reflected the disease characteristics. In our study, LIMMA package and t-test were used to identify DEGs between the two groups, following by the multiple correction test using Benjamini & Hochberg ([@b13-etm-0-0-7310]) method based on false discovery rate (FDR). DEGs were subsequently extracted using the criteria of FDR \<0.05. These identified DEGs were used to build a gene network.

### Establishment of multi-omics composite network

Six data sets (denoted by six networks) were combined to build a composite network, and six networks were called gene, phenotype, phenotype-gene, metabolite, gene-metabolite, and phenotype-metabolite networks.

### Construction of gene network

In our study, all human protein-protein interactions (PPIs) having combine-scores (1,048,576 interactions) were obtained from STRING to establish the background PPI network. After we removed the duplicated PPIs, and transformed proteins into human gene symbols, 1,515,370 highly correlated gene-gene interactions covering 16,785 genes were extracted to construct a seed PPI network (combine-score not less than 0.8 was used herein). Next, we took the intersection between the 16,785 genes in the seed PPI network and DEGs to establish the informative gene-gene network.

### Construction of metabolite network

To begin with, there were 4,994 human metabolites obtained from the KEGG, HMDB, Reactome, MSEA ([@b14-etm-0-0-7310]), as well as SMPDB ([@b15-etm-0-0-7310]). Afterwards, the metabolite-metabolite interactions of human as well as their corresponding confidence scores were extracted from STITCH ([@b16-etm-0-0-7310]). At the end, overall 3,764 human metabolites as well as 74,667 human metabolite-metabolite interactions were acquired.

### Establishment of phenotype network

A total of 5,080 phenotypes as well as the scores exist in the phenotype-phenotype similarity associations ([@b17-etm-0-0-7310]). Relying on the phenotype-phenotype similarity associations, a phenotype network was constructed.

### Construction of gene-metabolite association network

In order to obtain gene-metabolite interactions, the chemical and gene associations of human and the corresponding confidence scores were first extracted from the STITCH. After that, based on the 4,994 human metabolites, we gained human metabolite and gene associations. When removing the metabolites not included in the metabolite network mentioned above and eliminating the genes not covered in the gene network described above, a total of 192,763 gene-metabolite interactions involving in 12,342 genes as well as 3,278 metabolites were gained.

### Construction of phenotype-gene association network

Phenotype-gene associations were picked out relying on the curated Morbid Map file of the OMIM database. After discarding the phenotypes that were not included in the phenotype network and the genes that were not involved in the gene network, there were 2,603 gene-phenotype associations (covering 1,715 genes as well as 1,886 phenotypes). The weighted score was determined as 1 for each phenotype-gene association.

### Establishment of phenotype-metabolite association network

After filtration, there were 664 associations between 388 metabolites and 149 phenotypes. In addition, we defined the weighted value as 1 for each phenotype-metabolite interaction.

### Establishment of a weighted composite network

To extract the potential metabolites, we merged the six networks mentioned above into a weighted composite network. Specific steps were described in Yao *et al* ([@b12-etm-0-0-7310]).

### Prioritizing candidate metabolites on the basis of the weighted multi-omics composite network

The known PO-related metabolites (CID: 5460164, and 123986) were extracted from the Human Metabolome Database (HMDB) ([@b18-etm-0-0-7310]) which gathers specific information of small-molecule metabolites of human as well as the disease phenotype data. The known PO-related genes were collected from the Morbid Map file of Online Mendelian Inheritance in Man (OMIM) ([@b19-etm-0-0-7310]). The corresponding seed genes of PO were CALCR, LRP5, VDR, COL1A1, ESR1, NPPB, CNR1, CNR2, COL1A2, which were deposited in the database of OMIM. The phenotype of PO was 166710 in OMIN. Next, we mapped these seed genes, the phenotype, and the known metabolites to the weighted multi-omics composite network.

In an attempt to obtain the candidate metabolite prioritization from the weighted composite network involved in the seed genes, the phenotype, and the known metabolites, RWR method was expanded to the multi-omics composite network ([@b20-etm-0-0-7310]). Based on the distance proximity of every candidate metabolite, candidate metabolites were scored and ranked. According to the interaction score, the top 50 metabolites were identified which were determined as the PO-prioritized metabolites.

Subsequently, co-expressed genes interacting with the top 50 metabolites were identified, and then, we ranked these co-expressed genes relying on the score distribution. Finally, we extracted the top 100 co-expressed genes.

The subnetwork of the top 50 metabolites obtained from the composite network, and the co-expressed network between the top 100 co-expressed genes and the top 50 metabolites were constructed. Significantly, degree analyses were performed for these two networks to further identify several important AF-related metabolites.

Results
=======

### Identification of DEGs and establishment of multi-omics composite network

In the present study, we applied DEGs to construct the gene network, hence, DEGs between the two groups were first extracted. Using the criteria of the FDR \<0.05, overall 601 genes were extracted as differential expression. The top 40 DEGs are listed in [Table I](#tI-etm-0-0-7310){ref-type="table"}. In this study, the PO-related metabolites were identified and prioritized by combining multi-omics data. Thus, in our study, a multi-omics composite network was first established through combining the information of genome, metabolome, and phenome. A total of 6 kinds of interactions were included in the multi-omics composite network. In this network, there were 9,360 nodes and 10,224,741 edges ([Table II](#tII-etm-0-0-7310){ref-type="table"}).

### Prioritization of the PO-related metabolites

A total of 10 disease-related genes of PO are deposited in OMIM database, including CALCR, LRP5, VDR, COL1A1, ESR1, NPPB, CNR1, CNR2, and COL1A2, which were downloaded and determined as seed genes. There were 2 known disease metabolites (5460164, and 123986) data on PO in HMDB, which were defined as the seed metabolites. In our analysis, the 2 seed metabolites, and the 10 seed genes were utilized as seeds to identify the candidate metabolites of PO. To illustrate the intrinsic mode of this computational approach, the metabolites of the composite network were ranked in descending order on the basis of the interaction scores. The top 50 metabolites were dissected, and shown in [Table III](#tIII-etm-0-0-7310){ref-type="table"}. The top 5 metabolites were respectively glucosylgalactosyl hydroxylysine (score = 0.027662), all-trans-5,6-Epoxyretinoic acid (score = 0.008912), tretinoin (TN) (score = 0.004934), colecalciferol (INN) (score = 0.000686), and rocaltrol (TN) (score = 0.000675). A subnetwork of the top 50 metabolites was extracted from the whole composite network, as shown in [Fig. 2](#f2-etm-0-0-7310){ref-type="fig"}.

Afterwards, the co-expressed genes were extracted, which had interactions with the top 50 metabolites according to the score ranking. On the basis of the pre-defined criteria, the top 100 co-expressed genes were identified, and the co-expressed network of the top 100 genes are shown in [Fig. 3](#f3-etm-0-0-7310){ref-type="fig"}. Following degree analysis for the co-expressed network, 3 metabolites had a degree \>50, including estraderm (degree = 64), triphosadenine (DCF) (degree = 57), and tretinoin (TN) (degree = 55). Significantly, tretinoin (TN) was the member of the top 5 metabolites, and estraderm was a metabolite with the seventh interaction score.

Discussion
==========

Postmenopausal women have a high incidence of osteoporosis because of simultaneous existence of many independent predisposing factors, including estrogen deficiency, calcium loss, as well as aging ([@b21-etm-0-0-7310]). Osteoporosis is a main public health concern globally, particularly in countries with large aging populations, for example, China ([@b22-etm-0-0-7310]). Thus, it is urgently needed to seek for novel effective therapy strategy as well as etiologic explanations for PO. For a better understanding of the potential molecular mechanisms of PO, we used a computational method to extract metabolites signatures in PO by integrating the information among genes, metabolites, and phenotype related to pathogenesis. Our study identified several important metabolites between PO and normal samples, including tretinoin (TN) and estraderm.

Ahmed *et al* ([@b23-etm-0-0-7310]) demonstrated that tretinoin can suppress osteoblast proliferation, and inhibit the production of alkaline phosphatase, osteocalcin and IL-6 in normal human osteoblasts. In addition, suppression of IL-6 generation in normal osteoblasts might contribute to bone abnormalities. Moreover, in another study, tretinoin has been implicated to be able to activate the differentiation and proliferation of osteoclasts, thereby enhancing bone absorption ([@b24-etm-0-0-7310]). The imbalance in bone resorption and formation results in bone loss during aging and osteoporosis ([@b25-etm-0-0-7310]). Furthermore, many studies have used tretinoin to construct the model of osteoporosis ([@b26-etm-0-0-7310]--[@b28-etm-0-0-7310]). Thus, we infer that tretinoin is important for bone absorption and may be a target to suppress bone loss related to PO.

PO is believed to result directly from the decreased endogenous estrogen in menopausal women ([@b2-etm-0-0-7310]). Estraderm is a kind of steroid hormone that is mainly secreted by ovaries, placenta or testicles, and it is the most biologically active estrogen. Low concentration estraderm has been implicated to influence the proliferation and differentiation of osteoblast in a positive way ([@b29-etm-0-0-7310]). Estrogens may enhance fractional gastrointestinal calcium absorption, and an increased calcium intake might play a role in promoting bone mass ([@b30-etm-0-0-7310]). Recently, researchers have demonstrated that the combination of calcium and estrogen results in a significant increase in bone mass of the femoral neck, relative to estrogen alone ([@b31-etm-0-0-7310]). In addition, increased calcium intake decreases bone loss of premenopausal women ([@b32-etm-0-0-7310],[@b33-etm-0-0-7310]).

In conclusion, we successfully extracted several important metabolites in PO on the basis of the combination of multi-omics data. Significantly, our identified metabolites (tretinoin and estraderm) are available as biomarkers to diagnose PO, and our study has established available therapeutic options (tretinoin and estraderm) for the treatment of PO. However, we must take several limitations into consideration. Firstly, there are many gene expression profiles on PO, but we only used E-GEOD-7429 dataset in our analysis. Hence, we will utilize other datasets on this disease to confirm our results. In addition, we used existing data to extract candidate metabolite biomarkers based on the bioinformatics method. Yet, our results have not been verified by experiments and this remains the main weak point of the present study. Consequently, future investigations are required to reveal the changes of these metabolites in the understanding of the progression procedure in PO based on animal experiments or patient tissues. Despite these disadvantages, we are satisfied as our findings could offer some preliminary evidence to reveal the potential candidate therapeutic strategies for PO. The application of specific regulation-related metabolites in PO may provide new insights for preventive and therapeutic strategies.
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###### 

The top 40 (DEGs).

  Gene symbols   FDR        Gene symbols   FDR
  -------------- ---------- -------------- ----------
  MAPK3          8.52E-09   UBQLN4         9.85E-05
  HAO2           8.21E-09   KIRREL         9.73E-05
  TMEM8B         7.38E-08   POMT1          9.04E-05
  PSTPIP1        5.52E-08   SNAI2          8.78E-05
  HGD            5.37E-08   CYB5R4         7.92E-05
  STK11          4.55E-08   ODF2           7.22E-05
  ARMCX4         1.61E-08   LOC728392      7.21E-05
  SETD3          7.71E-07   ZNHIT3         8.36E-04
  NEO1           7.39E-07   XDH            8.12E-04
  ACKR1          7.12E-07   GALR1          7.49E-04
  PRG3           6.53E-07   PIGK           7.12E-04
  BEGAIN         5.69E-07   PRX            7.05E-04
  NRXN1          4.27E-07   PTOV1-AS2      7.01E-04
  ZNF446         3.95E-07   SULT1A2        6.82E-04
  C7             3.20E-07   ABT1           7.31E-04
  NBR2           3.18E-07   PAQR4          7.19E-04
  ISYNA1         4.39E-06   PAM16          6.97E-04
  RGSL1          4.15E-06   TMEM92-AS1     6.02E-04
  ODF1           1.85E-06   EVX1           3.18E-04
  SLC26A3        1.56E-06   CD1A           1.71E-04

DEGs, differentially expressed genes; FDR, false discovery rate.

###### 

Statistical information of the composite network.

  Statistics of the composite network        Nodes   Edges
  ------------------------------------------ ------- ------------
  Gene-gene network                          516     3325
  Metabolite-metabolite network              3764    74,667
  Phenotype-phenotype network                5080    10,140,046
  Gene-metabolite association network        516     3023
  Phenotype-gene association network         5080    2510
  Phenotype-metabolite association network   537     664
  Total                                      9360    10,224,741

###### 

The top 50 metabolites.

  Metabolite ID   Metabolite name                              Score
  --------------- -------------------------------------------- ----------
  122304          Glucosylgalactosyl hydroxylysine             0.027662
  5363137         All-trans-5,6-Epoxyretinoic acid             0.008912
  444795          Tretinoin (TN)                               0.004934
  5280795         Colecalciferol (INN)                         0.000686
  5280453         Rocaltrol (TN)                               0.000675
  445354          Retinol-(cellular-retinol-binding-protein)   0.000487
  5757            Estraderm (TN)                               0.000473
  6076            Cyclic AMP                                   0.000439
  5283731         Calcifediol                                  0.000407
  5280360         Cervidil (TN)                                0.0004
  439260          Nor adrenalin (TN)                           0.000369
  774             Histaminum (TN)                              0.000357
  945             Nitric oxide                                 0.000347
  5988            sucrose                                      0.000323
  5839            Aldosterone                                  0.00032
  6437063         all-trans-4-oxoretinoic acid                 0.000311
  9903            Lithocholic acid                             0.000305
  105071          Deoxypyridinoline                            0.000304
  5288826         Substitol (TN)                               0.000299
  2088            Alendronic acid (INN)                        0.000298
  172198          Delivert (TN)                                0.000296
  702             Dehydrated ethanol                           0.000277
  588             Creatinine (NF)                              0.000257
  888             magnesium ion                                0.000256
  6438629         all-trans-4-hydroxyretinoic acid             0.000255
  5202            serotonin                                    0.000254
  65064           Epigallocatechin 3-gallate                   0.000252
  681             Dopamine (INN)                               0.00025
  5281877         Retinoyl glucuronide                         0.000246
  969516          curcumin                                     0.00024
  449171          Panretin (TN)                                0.000232
  5957            Triphosadenine (DCF)                         0.000231
  105068          Pyridinoline                                 0.000227
  5881            Prasterone (INN)                             0.000225
  753             Moctanin (TN)                                0.000224
  445154          resveratrol                                  0.000222
  14985           α-Tocopherol                                 0.000221
  2733526         Tamoxifen (TN)                               0.00022
  5816            Adrenalin (TN)                               0.000218
  977             Oxygen (JP16/USP)                            0.000213
  60961           Adenocard (TN)                               0.00021
  89594           Habitrol (TN)                                0.000209
  23930           Manganese                                    0.000203
  444899          arachidonic acid                             0.000202
  5997            Cholesterol (TN)                             0.000201
  77999           Gaudil (TN)                                  0.0002
  1103            spermine                                     0.000198
  6830            guanosine 5′-triphosphate                    0.000195
  6041            Phenylephrine (INN)                          0.000195
  5920            Liothyronine (INN)                           0.000192
